The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer.

ABSTRACT:

Purpose

Panitumumab is a human monoclonal antibody targeting the epidermal growth factor receptor for the treatment of wild-type RAS metastatic colorectal cancer (mCRC). Currently, no dedicated clinical studies have evaluated the effect of organ impairment on the pharmacokinetics of panitumumab. Here, we present data from late phase studies of panitumumab in patients with mCRC and analyses of the effect of hepatic or renal impairment on the exposure of panitumumab.

Methods

From three multicenter, open-label, phase 2 and phase 3 studies, 349 and 351 patients were included in hepatic and renal function subgroup analyses, respectively. Patients who received IV panitumumab and serum exposures were compared to patients with varying degrees of hepatic and renal organ dysfunction.<

SUBMITTER: Liao MZ 

PROVIDER: S-EPMC8367910 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature